Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Tilray Medical erhält Zulassung für erstes medizinisches Cannabisextrakt in Portugal
Tilray Medical erhält Zulassung für erstes medizinisches Cannabisextrakt in Portugal

CANTANHEDE, Portugal, March 14, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. („Tilray“ oder das „Unternehmen“) (Nasdaq: TLRY; TSX: TLRY), ein führendes globales Cannabis- und

Tilray gibt internationales Cannabis-Update zum Meilenstein der deutschen Cannabis-Legalisierung
Tilray gibt internationales Cannabis-Update zum Meilenstein der deutschen Cannabis-Legalisierung

Die Freigabe von Cannabis in Deutschland eröffnet neue Möglichkeiten für Tilray auf dem potenziellen 3-Milliarden-Dollar-Markt für medizinische Produkte

Markt für medizinisches Cannabis in der

Canopy Growth: Neuer Online-Store, aber bekannte Zahlenschwäche...
Canopy Growth: Neuer Online-Store, aber bekannte Zahlenschwäche...

Canopy Growth (WKN: A140QA) goes online: Mit dem neuen Online-Store ShopCanopy versucht das Unternehmen aus Smith Falls, Kanada, seine E-Commerce-Aktivitäten zu intensivieren.

Doch bei einem

Canopy Growth: Das war der Befreiungsschlag!
Canopy Growth: Das war der Befreiungsschlag!

Wie ein zu Barrons gehörendes bedeutendes Online-Finanzportal berichtet, würden die Anleger billiges Marihuana bevorzugen. Canopy Growth (WKN: A140QA) sei dabei derjenige Branchenplayer, der im

Canopy Growth: Was Aurora kann...
Canopy Growth: Was Aurora kann...

...kann Canopy Growth (WKN: A140QA) schon lange. Nein, Canopy kann es sogar viel besser. Der Cannabis-Marktführer meldet heute Quartalszahlen, die im Gegensatz zu den Horrorzahlen von Aurora

Cannabis-Roundup: Canopy Growth & Aurora Cannabis
Cannabis-Roundup: Canopy Growth & Aurora Cannabis

Investoren strömen wieder in den Sektor. In den letzten Tagen konnten die Aktien von Canopy Growth (WKN: A140QA), Aurora Cannabis (WKN: A12GS7) oder Tilray (WKN: A2JQSC) stark hinzugewinnen.

Das

LION E-Mobility: Nach dem Deal ist vor der Rallye?
LION E-Mobility: Nach dem Deal ist vor der Rallye?

LION E-Mobility (WKN: A140QA) hatte mit der kanadischen Firma "The Lion Electric Co." vor Weihnachten einen „Multimillionen-Serienliefervertrag über BMW-Batterien“ geschlossen. Nun gibt das

LION E-Mobility: Serienliefervertrag für E-Schulbusse fix
LION E-Mobility: Serienliefervertrag für E-Schulbusse fix

LION E-Mobility (WKN: A140QA) wird Serienlieferant von Batterien für E-Schulbusse und E-LKWs. Dazu schloss das Unternehmen einen „potentiellen Multimillionen-Serienliefervertrag über BMW-Batterien“.

Canopy Growth: Wie gewonnen, so zerronnen?
Canopy Growth: Wie gewonnen, so zerronnen?

Zeitgleich mit Wechsel des Finanzchefs vom "Corona"-Brauer Constellation Brands an die Spitze von Canopy Growth (WKN: A140QA) scheint das Vertrauen in die grüne Wachstumsbranche zurückgekehrt (wir b

Canopy Growth: Die Spekulationsblase im Cannabis-Sektor ist geplatzt!
Canopy Growth: Die Spekulationsblase im Cannabis-Sektor ist geplatzt!

Es ist noch gar nicht so lange her, da rissen sich die Anleger um alle Aktien, die nur im entferntesten Sinne etwas mit Cannabis zu tun hatten. Denn schließlich sollte Cannabis ja plötzlich nahezu

Billionaire George Soros Is Betting Big Against These 2 Pharma Stocks
Billionaire George Soros Is Betting Big Against These 2 Pharma Stocks
Controversial billionaire George Soros may no longer be actively managing his namesake fund, Soros Fund Management, but the fund's quarterly activity remains a focal point for investors. The Soros....
Why Sanderson Farms, Valeant Pharmaceuticals International, and Criteo Slumped Today
Why Sanderson Farms, Valeant Pharmaceuticals International, and Criteo Slumped Today
Wall Street finally gave up some ground on Thursday, as the Dow Jones Industrials finished down more than 75 points. Major benchmarks generally posted modest losses of half a percent or less as....
Here's What's Behind Valeant Pharmaceuticals' 13% Drop
Here's What's Behind Valeant Pharmaceuticals' 13% Drop
Shares of Valeant Pharmaceuticals (NYSE: VRX), the embattled drugmaker that's primarily grown through price hikes and acquisitions this decade, tumbled as much as 13% on Thursday after receiving a....
What's Behind Valeant Pharmaceuticals Inc.'s 11% Move Higher?
What's Behind Valeant Pharmaceuticals Inc.'s 11% Move Higher?
Shares of Valeant Pharmaceuticals (NYSE: VRX), the embattled drugmaker that's predominantly grown through acquisitions and drug-price increases over the years, surged as much as 11% by 3 p.m. EST....
The Undeniable Reason Behind Valeant Pharmaceuticals Inc.'s 43% Rally in November
The Undeniable Reason Behind Valeant Pharmaceuticals Inc.'s 43% Rally in November
Shares of Valeant Pharmaceuticals (NYSE: VRX), an embattled drugmaker that had primarily grown by acquisitions and drug-price hikes in recent years, galloped higher by 43% in November, according....
Is Valeant Turning Things Around?
Is Valeant Turning Things Around?
Valeant Pharmaceuticals (NYSE: VRX) is notorious for its drug price gouging scandal a few years ago, an incident that caused the stock to tank and public opinion of the company plummeting to hit....
Here's What Overshadowed Valeant Pharmaceuticals in October, Pushing Its Shares Down 18%
Here's What Overshadowed Valeant Pharmaceuticals in October, Pushing Its Shares Down 18%
Shares of Valeant Pharmaceuticals (NYSE: VRX), an embattled drug developer that's primarily grown through price hikes and acquisitions over the years, tumbled 18% during October, according to data....
Is the Worst Behind Valeant Pharmaceuticals' Stock?
Is the Worst Behind Valeant Pharmaceuticals' Stock?
Valeant Pharmaceuticals' (NYSE: VRX) is knee-deep in a transformation that it hopes will allow it to regain its top-tier status with investors. The company's selling assets and funneling cash flow....
Why Valeant Pharmaceuticals International Stock Is Shooting Higher Today
Why Valeant Pharmaceuticals International Stock Is Shooting Higher Today
Valeant Pharmaceuticals International (NYSE: VRX) stock is up by double-digits today on heavy volume as the result of a better-than-expected third-quarter earnings release. Although the company....
Valeant Pharmaceuticals Posts a Huge Third-Quarter Profit -- but There's a Catch
Valeant Pharmaceuticals Posts a Huge Third-Quarter Profit -- but There's a Catch
Valeant Pharmaceuticals (NYSE: VRX) CEO Joe Papa has referred to the company in the past as "the turnaround opportunity of a lifetime." A key part of his turnaround strategy has been reducing the....
2 Figures That'll Tell Us if Valeant Pharmaceuticals' Business Is Improving
2 Figures That'll Tell Us if Valeant Pharmaceuticals' Business Is Improving
In recent years, a Valeant Pharmaceuticals (NYSE: VRX) quarterly earnings report was grounds to call out sick from work, bury yourself under the blankets, and pray you'd still have money left when....
Fighting Debt Demons, Valeant Pharmaceuticals Just Priced a New Debt Offering
Fighting Debt Demons, Valeant Pharmaceuticals Just Priced a New Debt Offering
The theme of 2017 for embattled drug developer Valeant Pharmaceuticals (NYSE: VRX) is "baby steps." After a miserable 2015 and 2016, which saw the company get buried under debt and accused of....
3 Top Stocks in Healthcare
3 Top Stocks in Healthcare
Healthcare stocks are hot this year. The sector-tracking iShares S&P Global Healthcare index has already tacked on a 17% gain this year.If you're looking to catch a ride on the healthcare....
How Low Does Valeant Pharmaceuticals' Debt Really Need to Go?
How Low Does Valeant Pharmaceuticals' Debt Really Need to Go?
There's as much of a chance that Valeant Pharmaceuticals (NYSE: VRX) wipes out its debt of nearly $28.5 billion anytime soon as there is of Donald Trump receiving a birthday present from football....
This Clear Catalyst Sent Valeant Pharmaceuticals Intl. Inc. 18% Lower in August
This Clear Catalyst Sent Valeant Pharmaceuticals Intl. Inc. 18% Lower in August
Shares of Valeant Pharmaceuticals (NYSE: VRX), a drugmaker that has predominantly grown via acquisitions over the years, plunged by 18% during August, according to data from S&P Global Market....